Table 3.

Multivariate analysis of graft and patient survival

VariableECD HRa (P Value)
(95% CI)DGF HRb (P Value)
(95% CI)Recipientc DM HR (P Value)
(95% CI)Induction HRd (P Value)
(95% CI)
Group 1: graft survival1.90 (0.03)2.17 (0.01)1.48 (0.17)Univariate: antithymocyte globulin (0.85)
(1.07–3.38)(1.24–3.77)(0.85–2.58)Alemtuzumab (0.52)
Group 1: patient survival1.97 (0.05)1.96 (0.04)2.05 (0.03)Univariate: antithymocyte globulin (0.98)
(0.99–3.90)(1.02–3.76)(1.08–3.89)Alemtuzumab (0.50)
Group 2: graft survival1.23 (0.41)1.93 (0.01)1.27 (0.35)Antithymocyte globulin 2.42 (0.01)
(0.75–2.01)(1.18–3.17)(0.77–2.08)(1.22–4.78)
Group 2: patient survivalUnivariate (0.25)2.49 (0.004)1.51 (0.19)Antithymocyte globulin 3.18 (0.001)
(1.34–4.60)(0.81–2.80)(1.59–6.37)
  • Univariate P values indicate that the differences were nonsignificant and were not included in the multivariate analysis. ECD, expanded-criteria donor; HR, hazard ratio; CI, confidence interval; DGF, delayed graft function; DM, diabetes mellitus.

  • a Compared with standard-criteria donor.

  • b Compared with no DGF.

  • c Compared with no DM.

  • d Compared with basiliximab.